This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
French green chemistry specialist Global Bioenergies announced the delivery of a first batch of sustainable cosmetic ingredients to cosmetics heavyweight L’Oréal. It was produced as part of the ISOPROD project, […]
More than 4,000 participants from all over the globe visited Berlin in early November to take part in this years BIO-Europe. The event continues to be on the upswing […]
US biotech company Regeneron Pharmaceuticals revealed plans to create some 300 new jobs in Ireland’s Limerick County. The jobs form part of a US$100m (85m) expansion plan for the company’s […]
Portuguese biotech company Immunethep has convinced the Bill & Melinda Gates Foundation to hand out a grant to test its antibody against the bacterial extracellular virulence factor GAPDH.
Dutch Uniqure BV launched a public offering of five million shares of common stock. Underwriters over-allotment will be an additional 750,000 shares.
The Leukemia & Lymphoma Society (LLS) and Polish drug developer Selvita SA have entered a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients […]
Gene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current […]
Sweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.
Johnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
UKs biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and […]